Thus, specific targeting of VEGFR3 signaling to improve lymphatic function either by ligand (VEGF-C/D) overexpression or by controlling chronic inflammation with lymphatic dysfunction related obesity and additional metabolic disorders. This evidence concerns the gene VEGFC and metabolic disease.